As cancer cells become hypoxic, they express angiogenic factors such as hypoxia inducible factor (HIF), vascular endothelial growth factor A (VEGFA), platelet-derived growth factor (PDGF) or angiopoietin 2 (ANGPT2) as well as proangiogenic chemokines and receptors to initiate neo-angiogenesis (a process termed “angiogenic switch”) (Carmeliet and Jain, 2000; Potente et al., 2011). This evidence concerns the gene ANGPT2 and cancer.